Aarti Pharma Labs
728.45
+8.75(+1.22%)
Market Cap₹6,603.20 Cr
PE Ratio30.45
IndustryHealthcare
Company Performance:
1D+1.22%
1M-5.24%
6M-11.02%
1Y-1.59%
5Y+152.71%
View Company Insightsright
More news about Aarti Pharma Labs
02Feb 26
Aarti Pharmalabs Limited Schedules Q3FY26 Earnings Conference Call for February 10, 2026
Aarti Pharmalabs Limited has scheduled its Q3FY26 earnings conference call for February 10, 2026 at 4:00 PM IST. The group meeting will feature Chairman Mr. Rashesh Gogri, Vice Chairperson Mrs. Hetal Gogri Gala, and CFO Mr. Piyush Lakhani discussing quarterly financial results. The company has provided domestic and international dial-in access, with toll-free numbers available for Hong Kong, Singapore, USA, and UK participants.
 no imag found
01Jan 26
Aarti Pharmalabs Limited Appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D
Aarti Pharmalabs Limited has appointed Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D effective January 01, 2026, following Board approval based on Nomination and Remuneration Committee recommendation. Dr. Bandichhor brings 25 years of experience in API-R&D and Process Chemistry, with strong academic credentials including M.Sc. degrees and Ph.D. in Chemistry, plus postdoctoral training from universities in Germany and USA. He was previously associated with Dr. Reddy's Laboratories in Hyderabad.
 no imag found
17Nov 25
Aarti Pharmalabs Reports 11% Revenue Growth in Q2FY26, Revises EBITDA Growth Guidance
Aarti Pharma Labs reported a 11% year-on-year revenue growth for Q2FY26, reaching INR 417.00 crores. However, EBITDA declined to INR 75.00 crores from INR 85.00 crores, and PAT decreased to INR 31.00 crores from INR 48.00 crores. The company's Xanthine Derivatives segment contributed 51% to turnover, API and Intermediates 39%, and CDMO-CMO Services 10%. The Atali plant was inaugurated in September, and Xanthine expansion is progressing as planned. Aarti Pharma Labs revised its FY26 EBITDA growth guidance to 8-12% year-on-year, with the CDMO-CMO business expected to exceed earlier projections.
 no imag found
09Nov 25
Aarti Pharmalabs Reports Strong Q2 Performance with 11% Revenue Growth
Aarti Pharma Labs announced unaudited Q2 and H1 FY2026 results. Q2 standalone revenue increased 11.2% to Rs 417.29 crore, with net profit up 45.3% to Rs 30.85 crore. H1 FY2026 revenue grew 2.8% to Rs 792.60 crore, while net profit rose 8.9% to Rs 52.08 crore year-over-year. The company operates in the pharmaceuticals segment and has global subsidiaries including Aarti USA Inc and Aarti Pharmachem Ltd. A joint venture with Ganesh Polychem Limited became effective from April 1, 2025.
 no imag found
09Nov 25
Aarti Pharma Labs Bolsters Leadership with Two Key Senior Management Appointments
Aarti Pharma Labs Limited has announced two significant appointments to its senior management team, effective November 10, 2025. Mr. Hemant Gundare, with a doctorate in Green Chemistry, joins as Head Corporate - EHS (Environment, Health & Safety). Mr. Shrihari S. Mane, with 32 years of experience in API manufacturing, has been appointed as Chief Technology Officer (API). These appointments, approved by the Board of Directors on November 9, 2025, aim to enhance the company's environmental sustainability, safety practices, and technological capabilities in API manufacturing.
 no imag found
Aarti Pharma Labs
728.45
+8.75
(+1.22%)
1 Year Returns:-1.59%
Industry Peers
Sun Pharmaceutical
1,762.10
(-1.32%)
Divis Laboratories
6,453.00
(-0.32%)
Torrent Pharmaceuticals
4,356.50
(-0.98%)
Cipla
1,347.30
(-0.80%)
Dr Reddys Laboratories
1,289.80
(-2.24%)
Lupin
2,322.00
(-0.05%)
Zydus Life Science
925.20
(-1.42%)
Mankind Pharma
2,250.00
(-1.30%)
Aurobindo Pharma
1,232.60
(+0.97%)
Alkem Laboratories
5,660.00
(-1.60%)